Munich (Germany), September 16, 2018: ImevaX GmbH, a specialist in rapid diagnostic tests and developing vaccines against pathogens of chronic infectious diseases, especially H. pylori infections, announced today the appointment of Dr James Neil Phillips as Chief Executive.

Dr James Neil Phillips has extensive international management experience in the pharmaceutical industry. Dr Phillips is a registered Physician who also holds an MBA from Cass Business School in London. Before joining ImevaX, Dr Phillips was the CEO of Midatech Pharma for five years. Dr Phillips holds two non-executive directorships in Europe - PreciHealth SA & Herantis Pharma OY.  He was President of EUSA Pharma Europe in its key growth phase prior to its sales in 2012 to Jazz Pharma, CEO & founder in Talisker Pharma (sold in 2006 to EUSA Pharma) and also SVP Corporate Development at EUSA; he founded Talisker Pharma in 2004 which was acquired by EUSA in 2006. Dr Phillips was also Chairman of Prosonix Ltd between 2007-12 prior to its successful sale to Circassia. Dr Phillips previously worked for Johnson & Johnson and Novartis as a senior executive.

 “I am honoured to have been elected as the new CEO of ImevaX”, Dr Phillips commented. “ImevaX is in the phase searching for partners in the industry and I hope to support success and creating value for the shareholders.”

Dr Phillips succeeds Dr Roskrow, who had acted as CEO since September 2015 until September 2018.

About ImevaX
ImevaX is a biopharmaceutical company founded in 2014 based in Munich, Germany. The focus is to combat chronic and nosocomial infections by creating specific vaccines and develop new generations of rapid diagnostic tests.

For further information, please contact:

Volker Wedershoven
Chief Financial Officer
ImevaX GmbH
Tel: +49 (0) 89 41 424 55 0
Email: volker.wedershoven@imevax.com